PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...

CLPH-291 is under development for the treatment of Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, Hermansky-Pudlak syndrome, and Wiskott-Aldrich syndrome. It is being developed based on FPH ...

Nearly 200 nations at the Cop28 climate summit in Dubai agreed to the deal, which calls on them to "transition away" from ... who had called for the term "phase out" of fossil fuels to be used ...

Deconfined quantum criticality represents a novel class of phase transitions that fall outside ... material candidates show a weakly-first order transition. Here the authors introduce a Nordic ...